Living Donor Lobar Lung Transplantation: Current Status and Future Directions

2005 ◽  
Vol 37 (9) ◽  
pp. 3983-3986 ◽  
Author(s):  
M.L. Barr ◽  
F.A. Schenkel ◽  
M.E. Bowdish ◽  
V.A. Starnes
Keyword(s):  
Lung Transplantation ◽  
Living Donor ◽  
Current Status ◽  
Future Directions

Current Status and Future Directions of Nanoparticulate Strategy for Cancer Immunotherapy

2016 ◽  
Vol 17 (8) ◽  
pp. 755-762 ◽  
Author(s):  
Xu Zhou ◽  
Renhe Liu ◽  
Shuo Qin ◽  
Ruilian Yu ◽  
Yao Fu
Keyword(s):  
Cancer Immunotherapy ◽  
Current Status ◽  
Future Directions

scholarly journals New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions

2020 ◽  
Vol 11 ◽  
Author(s):  
Nathaniel Edward Bennett Saidu ◽  
Chiara Bonini ◽  
Anne Dickinson ◽  
Magdalena Grce ◽  
Marit Inngjerdingen ◽  
...  
Keyword(s):  
Graft Versus Host Disease ◽  
Current Status ◽  
Future Directions ◽  
Host Disease ◽  
Graft Versus Host ◽  
New Approaches

scholarly journals Current Status of Human Papillomavirus-Related Head and Neck Cancer: From Viral Genome to Patient Care

2021 ◽  
Author(s):  
Haoru Dong ◽  
Xinhua Shu ◽  
Qiang Xu ◽  
Chen Zhu ◽  
Andreas M. Kaufmann ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Head And Neck ◽  
Treatment Strategies ◽  
Hpv Infection ◽  
Immune Checkpoint Blockade ◽  
Current Status ◽  
Future Directions ◽  
Sequencing Technologies ◽  
E6 And E7 ◽  
The Continuum

AbstractHuman papillomavirus (HPV) infection identified as a definitive human carcinogen is increasingly being recognized for its role in carcinogenesis of human cancers. Up to 38%–80% of head and neck squamous cell carcinoma (HNSCC) in oropharyngeal location (OPSCC) and nearly all cervical cancers contain the HPV genome which is implicated in causing cancer through its oncoproteins E6 and E7. Given by the biologically distinct HPV-related OPSCC and a more favorable prognosis compared to HPV-negative tumors, clinical trials on de-escalation treatment strategies for these patients have been studied. It is therefore raised the questions for the patient stratification if treatment de-escalation is feasible. Moreover, understanding the crosstalk of HPV-mediated malignancy and immunity with clinical insights from the proportional response rate to immune checkpoint blockade treatments in patients with HNSCC is of importance to substantially improve the treatment efficacy. This review discusses the biology of HPV-related HNSCC as well as successful clinically findings with promising candidates in the pipeline for future directions. With the advent of various sequencing technologies, further biomolecules associated with HPV-related HNSCC progression are currently being identified to be used as potential biomarkers or targets for clinical decisions throughout the continuum of cancer care.

scholarly journals Understanding and assessing flood risk in Vietnam: Current status, persisting gaps, and future directions

2021 ◽  
Author(s):  
Minh Tu Nguyen ◽  
Zita Sebesvari ◽  
Maxime Souvignet ◽  
Felix Bachofer ◽  
Andreas Braun ◽  
...  
Keyword(s):  
Flood Risk ◽  
Current Status ◽  
Future Directions

scholarly journals Biased ligands at opioid receptors: Current status and future directions

2021 ◽  
Vol 14 (677) ◽  
pp. eaav0320
Author(s):  
Tao Che ◽  
Hemlata Dwivedi-Agnihotri ◽  
Arun K. Shukla ◽  
Bryan L. Roth
Keyword(s):  
Opioid Receptors ◽  
Current Status ◽  
Functional Responses ◽  
Future Directions ◽  
Health Crisis ◽  
Biased Agonism ◽  
Opioid Ligands ◽  
Therapeutic Benefits ◽  
Ligand Discovery ◽  
Opioid Medications

The opioid crisis represents a major worldwide public health crisis that has accelerated the search for safer and more effective opioids. Over the past few years, the identification of biased opioid ligands capable of eliciting selective functional responses has provided an alternative avenue to develop novel therapeutics without the side effects of current opioid medications. However, whether biased agonism or other pharmacological properties, such as partial agonism (or low efficacy), account for the therapeutic benefits remains questionable. Here, we provide a summary of the current status of biased opioid ligands that target the μ- and κ-opioid receptors and highlight advances in preclinical and clinical trials of some of these ligands. We also discuss an example of structure-based biased ligand discovery at the μ-opioid receptor, an approach that could revolutionize drug discovery at opioid and other receptors. Last, we briefly discuss caveats and future directions for this important area of research.

Sign in / Sign up

Export Citation Format

Share Document